ExcellGene is a CMO/CRO/CDO providing services and production in the field of recombinant biologics made with animal cells in bioreactors (DNA to product), such as proteins and virus vectors (AAV). Numerous innovations assure high yield, fast development time and early entry to clinic.
Products, services, technology
Transfection reagents and media; Cell culture media for CHO, HEK and insect cells; Feeds for high performance in fed-batch processes (CHEMICALLY DEFINED); cGMP compliant manufacturing processes, scalable to any volumetric scale of operation.
Cooperation possibilities
ExcellGene offers licenses to key technologies in transfection, for high performance cell lines (CHOExpress®, HEKExpress®, JumpExpress®, CHO4Tx®) and provides partnership alliances with companies that have pipelines of development projects.
- http://www.excellgene.com
- +41 24 471 96 60
- Send an email
- Prof. Dr. Florian Wurm
Some insights
ExcellGene addresses an important medical need in developing manufacturing processes and products derived thereof for antibodies, fusion molecules, virus antigens, hormones, etc.
Without any funding from investors, ExcellGene has been grown from humble beginnings to a globally recognized scientific and technological leader in the generation and development of highest yielding manufacturing processes for recombinant proteins using both CHO and HEK293 derived cell lines.
ExcellGene has been an innovative driver of excellence in manufacturing technology for CHO and HEK-293 cells. A a novel bioreactor system based on orbital shaking was invented by Maria J. Wurm, CEO of the company. Today millions of these bioreactors are used by leading pharmaceutical companies.
